Olmesartan Medoxomil/Amlodipine/Hct Teva (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil/Amlodipine/HCT is a combination antihypertensive used to manage elevated blood pressure across several clinical presentations.

• Essential hypertension: lowers both systolic and diastolic pressure in patients with primary hypertension.
• Isolated systolic hypertension: provides arterial dilation and volume reduction to control high systolic readings.
• Hypertension with fluid retention: adds diuretic effect to improve blood pressure control when edema is present.

• The combination works through three complementary mechanisms: olmesartan medoxomil blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release; amlodipine inhibits calcium influx into vascular smooth muscle, causing arterial dilation; and hydrochlorothiazide promotes renal excretion of sodium and water, reducing plasma volume. Together these actions produce a synergistic reduction in systemic blood pressure.

The following adverse reactions have been reported with the combination product.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain often related to blood pressure changes.
• Peripheral edema: swelling of the ankles or feet.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Electrolyte imbalance: significant changes in potassium or sodium levels.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety factors.

• Renal function: monitor serum creatinine and potassium regularly.
• Pregnancy: contraindicated (Category D) due to potential fetal harm.
• Elderly patients: start at low dose and watch for orthostatic hypotension.
• Concomitant potassium‑sparing agents: risk of hyperkalemia, requires monitoring.
• Store at ambient temperature: keep in the original container, protect from moisture.

Olmesartan Medoxomil/Amlodipine/HCT may interact with other medicines; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): increased risk of renal failure.
• Potassium supplements or ACE inhibitors: heightened risk of hyperkalemia.
• Lithium: potential for elevated lithium concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect.
• Cyclosporine: can raise serum creatinine levels.
• Beta‑blockers: additive hypotensive effect may require dose adjustment.